kabutan

TMS Co., Ltd.(4891) Summary

4891
TSE Growth
TMS Co., Ltd.
150
JPY
0
(0.00%)
Apr 28, 3:30 pm JST
0.94
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
2.50
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
150 JPY 0.94 USD
Previous Close Apr 27
150 JPY 0.94 USD
High Apr 28, 12:34 pm
151 JPY 0.94 USD
Low Apr 28, 9:06 am
146 JPY 0.91 USD
Volume
321,400
Trading Value
0.05B JPY 0.30M USD
VWAP
148.83 JPY 0.94 USD
Minimum Trading Value
15,000 JPY 94 USD
Market Cap
6.83B JPY 0.04B USD
Number of Trades
202
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Mid
1-Year Average
200
1-Year High Jul 18, 2025
1,749
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 3,567,300
Apr 17, 2026 0 3,659,500
Apr 10, 2026 0 3,900,300
Apr 3, 2026 0 3,762,100
Mar 27, 2026 0 3,786,300
Company Profile
TMS Co., Ltd. is a drug discovery bioventure originating from Tokyo University of Agriculture and Technology. The company has partnered with US-based Biogen for its acute ischemic stroke drug candidate.
Sector
Pharmaceuticals
TMS Co., Ltd., a drug discovery bioventure spun off from Tokyo University of Agriculture and Technology, focuses its business on developing TMS-007, a drug candidate for acute ischemic stroke. TMS-007 possesses both thrombolytic and anti-inflammatory properties and has shown promising results in Phase IIa clinical trials. The company has partnered with Hong Kong-based JIXING and retains development and marketing rights for Japan. TMS Co., Ltd. also has multiple pipelines, including TMS-008 for acute kidney injury and cancer cachexia, and JX09, a candidate for hypertension treatment. The company's growth strategy involves in-licensing and developing drug seeds from academia through collaborative research with universities and other institutions, aiming to expand into the global market.